CO-DIAGNOSTICS, INC. Form 8-K (March 15, 2022)

Summary

Current report on Form 8-K of Co-Diagnostics, Inc. reporting an event dated March 15, 2022. Under Item 8.01 the company announced that its Board of Directors authorized a share repurchase program allowing it to repurchase up to $30 million of its common stock. The filing states that the program does not obligate the company to acquire any particular number of shares and may be suspended or discontinued at any time at the company's discretion. A press release is furnished as Exhibit 99.1, and /s/ Brian Brown, Chief Financial Officer (Principal Financial and Accounting Officer), signed March 15, 2022.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED
STATES

SECURITIES
AND EXCHANGE COMMISSION

Washington,
D.C. 20549

FORM 8-K

CURRENT
REPORT

Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date
of Report (Date of earliest event reported): March 15, 2022

CO-DIAGNOSTICS,
INC.

(Exact
name of registrant as specified in its charter)

Utah | 001-38148 | 46-2609363
(State
 or other jurisdiction of
 incorporation) | (Commission File
 Number) | (IRS
 Employer Identification
 No.)

2401
S. Foothill Drive , Suite D

Salt
Lake City , UT 84109

(Address
of principal executive offices, including Zip Code)

Registrant’s
telephone number, including area code: (801) 438-1036

N/A

(Former
name or former address, if changed since last report)

Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:

☐ | Written
 communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ | Soliciting
 material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ | Pre-commencement
 communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ | Pre-commencement
 communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities
registered pursuant to Section 12(b) of the Act:

Title
 of each class: | Trading
 Symbol(s): | Name
 of each exchange on which registered:
Common
 Stock, par value $0.001 per share | CODX | The NASDAQ Capital Market

Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging
growth company ☒

If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure

On March 15, 2022, Co-Diagnostics,
Inc. (the “Company”) issued a press release. A copy of the press release is furnished as Exhibit 99.1 to
this report and is incorporated herein by reference.

Item 8.01 Other Information

On
March 15, 2022, the Company announced that its Board of Directors authorized a share repurchase program that would allow the Company
to repurchase up to $30 million of its common stock (the “Repurchase Program”). The Repurchase Program
does not obligate the Company to acquire any particular number of common shares, and the Repurchase Program may be suspended
or discontinued at any time at the Company’s discretion. The timing and amount of any share repurchases under the Repurchase
Program will be determined by Company management at its discretion based on ongoing assessments of the capital needs of the business,
the market price of the Company’s common stock, corporate and regulatory requirements, and general market conditions. Share repurchases
under the program may be made through a variety of methods, which may include open market purchases, in block trades, accelerated share
repurchase transactions, exchange transactions, the use of trading plans intended to qualify under Rule 10b5-1 under the Securities Exchange
Act of 1934, as amended, or any combination of such methods.

EXHIBIT
INDEX

Exhibit
 No. | Description
99.1 | Press Release dated March 15, 2022
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

CO-DIAGNOSTICS,
 INC.
Date: | March
 15, 2022 | By: | /s/
 Brian Brown
Brian
 Brown
Chief
 Financial Officer
(Principal
 Financial and Accounting Officer)

File and source

File

SEC_CODX_8-K_filed2022-03-15_0001493152-22-006811.htm

Size

40,702 bytes

SHA-256

9e25a25e3895df638894a843e5b9318ea3bef04445bf75b73007cc4dc9b2df98

Our copy

SEC_CODX_8-K_filed2022-03-15_0001493152-22-006811.htm

Original

www.sec.gov